IDXG vs. GCTK, PSTV, PYPD, NURO, VAPO, VVOS, AFIB, TMDIF, STSS, and UTRS
Should you be buying Interpace Biosciences stock or one of its competitors? The main competitors of Interpace Biosciences include GlucoTrack (GCTK), Plus Therapeutics (PSTV), PolyPid (PYPD), NeuroMetrix (NURO), Vapotherm (VAPO), Vivos Therapeutics (VVOS), Acutus Medical (AFIB), Titan Medical (TMDIF), Sharps Technology (STSS), and Minerva Surgical (UTRS). These companies are all part of the "surgical & medical instruments" industry.
GlucoTrack (NASDAQ:GCTK) and Interpace Biosciences (NASDAQ:IDXG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.
GlucoTrack has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are owned by institutional investors. 3.3% of GlucoTrack shares are owned by company insiders. Comparatively, 6.5% of Interpace Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, GlucoTrack had 2 more articles in the media than Interpace Biosciences. MarketBeat recorded 2 mentions for GlucoTrack and 0 mentions for Interpace Biosciences. Interpace Biosciences' average media sentiment score of 1.43 beat GlucoTrack's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media.
GlucoTrack has higher earnings, but lower revenue than Interpace Biosciences. Interpace Biosciences is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.
GlucoTrack has a net margin of 0.00% compared to GlucoTrack's net margin of -4.32%. GlucoTrack's return on equity of 0.00% beat Interpace Biosciences' return on equity.
Interpace Biosciences received 319 more outperform votes than GlucoTrack when rated by MarketBeat users.
Summary
GlucoTrack beats Interpace Biosciences on 7 of the 13 factors compared between the two stocks.
Get Interpace Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Interpace Biosciences Competitors List
Related Companies and Tools